Related Experiment Video
Updated: Jun 6, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Identification and biological activities of a new antiangiogenic small molecule that suppresses mitochondrial
Ki Hyun Kim1, Ju Yeol Park, Hye Jin Jung
1Chemical Genomics National Research Laboratory, Department of Biotechnology, Translational Research Center for Protein Function Control, College of Life Science & Biotechnology, Yonsei University, Seoul 120-749, Republic of Korea.
Abstract:
Mitochondrial reactive oxygen species (ROS) are associated with multiple cellular functions such as cell proliferation, differentiation, and apoptosis. In particular, high levels of mitochondrial ROS in hypoxic cells regulate many angiogenesis-related diseases, including cancer and ischemic disorders. Here we report a new angiogenesis inhibitor, YCG063, which suppressed mitochondrial ROS generation in a phenotypic cell-based screening of a small molecule-focused library with an ArrayScan HCS reader. YCG063 suppressed mitochondrial ROS generation under a hypoxic condition in a dose-dependent manner, leading to the inhibition of in vitro angiogenic tube formation and chemoinvasion as well as in vivo angiogenesis of the chorioallantoic membrane (CAM) at non-toxic doses. In addition, YCG063 decreased the expression levels of HIF-1α and its target gene, VEGF. Collectively, a new antiangiogenic small molecule that suppresses mitochondrial ROS was identified. This new small molecule tool will provide a basis for a better understanding of angiogenesis driven under hypoxic conditions.
Insights
Researchers identified YCG063, a novel small molecule that inhibits angiogenesis by suppressing mitochondrial reactive oxygen species (ROS) generation, particularly under hypoxic conditions. This discovery offers a new tool for studying diseases linked to angiogenesis.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Mitochondrial reactive oxygen species (ROS) play crucial roles in cellular functions.
- Elevated mitochondrial ROS in hypoxic cells are implicated in angiogenesis-related diseases like cancer and ischemic disorders.
Purpose of the Study:
- To identify and characterize a novel small molecule inhibitor of angiogenesis.
- To investigate the mechanism of action focusing on mitochondrial ROS suppression.
Main Methods:
- Phenotypic cell-based screening using an ArrayScan HCS reader to identify small molecules.
- In vitro assays for angiogenic tube formation and chemoinvasion.
- In vivo angiogenesis assay using the chorioallantoic membrane (CAM).
- Western blot analysis for HIF-1α and VEGF expression.
Main Results:
- YCG063 was identified as an inhibitor that suppresses mitochondrial ROS generation in a dose-dependent manner under hypoxia.
- YCG063 significantly inhibited in vitro angiogenesis (tube formation, chemoinvasion) and in vivo angiogenesis (CAM assay) at non-toxic concentrations.
- YCG063 decreased the expression of hypoxia-inducible factor 1-alpha (HIF-1α) and its target gene vascular endothelial growth factor (VEGF).
Conclusions:
- A novel anti-angiogenic small molecule, YCG063, was discovered that targets mitochondrial ROS.
- YCG063 demonstrates therapeutic potential for angiogenesis-driven diseases by inhibiting ROS and downstream signaling pathways.
- This compound serves as a valuable tool for further research into hypoxia-driven angiogenesis.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Mitochondrial Membranes
